Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › VA › Abingdon › NPI 1760949127
Physician

Starting Point of Virginia, P.C.

Starting Point of Virginia, P.C. was paid $28.98M by Medicaid between Dec 2018 and Dec 2024, across 29 billing codes. Its largest line is G9012, Other specified case management service not elsewhere classified — 27% of everything it billed.

33Billing provider infoSTARTING POINT OF VIRGINIA, P.C.
ABINGDON, VA 24210
33aNPI1760949127assigned 02/21/2019
28Total paid$28.98M
24GClaims408,448
24DCodes billed29
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers

Next to other Addiction Medicine (Psychiatry & Neurology) Physician providers in Virginia

Rank by total paid#1 of 6
Median peer was paid$63K
This provider vs. median459×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official MCCORMAC, RUPERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201840$0.00
201916,635$397K
202033,978$2.40M
202192,331$6.90M
202275,843$6.00M
202396,052$6.54M
2024incomplete93,569$6.73M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
G9012 Other specified case management service not elsewhere classified 27% 39,528 36,062 $7.95M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 18% 95,724 55,784 $5.23M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 14% 40,553 18,348 $4.04M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 9.7% 20,184 11,998 $2.81M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 8.6% 49,334 36,671 $2.49M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 8.2% 34,796 30,014 $2.38M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 6.3% 27,753 18,273 $1.83M
H0004 Behavioral health counseling and therapy, per 15 minutes 3.4% 46,262 32,909 $988K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 1.6% 6,515 3,213 $465K
80305 1.1% 28,996 21,134 $314K
H0014 Alcohol and/or drug services; ambulatory detoxification <1% 1,790 1,676 $211K
90791 Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation <1% 848 805 $93K
17 more codes
99408 <1% 2,830 $60K
90832 Psychotherapy session, about 30 minutes <1% 851 $24K
99406 <1% 3,824 $23K
H0020 Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) <1% 3,012 $23K
S0109 Methadone, oral, 5 mg <1% 4,341 $17K
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) <1% 254 $16K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 59 $7K
99204 Doctor's office visit, new patient (more involved) <1% 37 $3K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 127 $2K
82075 <1% 415 $1K
99203 Doctor's office visit, new patient (routine) <1% 12 $966.01
81025 <1% 170 $941.70
99484 <1% 62 $470.01
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 44 $463.48
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 18 $442.78
H0005 Alcohol and/or drug services; group counseling by a clinician <1% 93 $406.00
H0047 Alcohol and/or other drug abuse services, not otherwise specified 0% 16 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMCCORMAC, RUPERT (CHIEF EXECUTIVE OFFICER)
Same official

Other billing entities under MCCORMAC, RUPERT

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.